Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC.

In contrast to vehicle-treated animals, animals treated with inhaled mosliciguat showed a trend toward smaller desaturation areas (intervention cycles [inhalation]) as well as a decrease in PAP under normoxic and broncho-occlusion cycles, which was even more pronounced 90 min after inhalation (intervention cycle 2 [inhalation]) (Fig. 8 A).

also in 53,322 other papers